Cynata Therapeutics Limited (ASX:CYP)

Market Cap	83.11M +59.9%
Revenue (ttm)	1.69M -3.0%
Net Income	-8.40M
EPS	-0.04
Shares Out	237.45M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	96,376
Average Volume	174,638
Open	0.3400
Previous Close	0.3300
Day's Range	0.3250 - 0.3500
52-Week Range	0.1400 - 0.4350
Beta	1.04
RSI	43.25
Earnings Date	Feb 20, 2026

About Cynata Therapeutics

Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company’s lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease. It is also involved in the development of CYP-004, which is in Phase 3 clinical trial used for the treatment of osteoarthritis; CYP-006TK, a n...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 2
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CYP

Financial Performance

In fiscal year 2025, Cynata Therapeutics's revenue was 1.89 million, a decrease of -18.59% compared to the previous year's 2.32 million. Losses were -9.39 million, -3.63% less than in 2024.